Karius

About

Karius provides genomic insights for infectious diseases to enable clinicians to make life-saving treatment decisions.

Redwood City,California,United States
101 - 250
https://kariusdx.com

Highlights

Details

Last Funding Type: Series B
Last Funding Money Raised: $165M
Industries: Biotechnology,Genetics,Health Care,Information Technology,Life Science
Founded date: Jan 1, 2014
Number Of Employee: 101 - 250
Operating Status: Active
Legal Name: Karius, Inc.

Karius is a life sciences company focused on generating genomic insights for infectious diseases with a liquid biopsy for infectious diseases. The Karius Test that helps clinicians make rapid, treatment decisions. By mapping each patient’s microbial landscape from a single blood draw, Karius moves closer to a vision of a world where infectious disease is no longer a major threat to human health. The Karius laboratory is CLIA-certified and CAP-accredited to perform high-complexity clinical laboratory testing.

Funding Rounds

Number of Funding Rounds

Total Funding Amount

6

$254M

Karius has raised a total of $254M in funding over 2 rounds. Their latest funding was raised on Mar 7, 2022 from a Series B round.

Announced Date	Round	Money Raised	Number of Investors	Lead Investors	Post Valuation
Mar 7, 2022	Series B	—	2	—	—	Detail
Jan 20, 2021	Series B	—	1	—	—	Detail
Feb 24, 2020	Series B	$165M	5	SoftBank Vision Fund	—	Detail
Nov 30, 2018	Debt Financing	$25M	1	Oxford Finance LLC	—	Detail
Aug 5, 2017	Series A	$59M	8	DCVC Lightspeed Venture Partners	—	Detail

Investors

Number of Lead Investors

Number of Investors

5

13

Karius is funded by 13 investors. SoftBank Vision Fund and Oxford Finance LLC are the most recent investors.

Investor Name	Lead Investor	Funding Round
SoftBank Vision Fund	Yes	Series B
Oxford Finance LLC	Yes	Debt Financing
DCVC	Yes	Series A
HBM Healthcare Investments AG	—	Series B
HBM Partners	—	Series B
General Catalyst	—	Series B
Khosla Ventures	—	Series B
Lightspeed Venture Partners	—	Series B
aMoon Fund	—	Series A
Innovation Endeavors	—	Series A